Essential Partners’s XBiotech XBIT Stock Holding History

Essential Partners’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-16	Closed	-$43	–	2936
2025 Q3	$43	Sell	16 -17	-52%	-$50	﹤0.01%	2584
2025 Q2	$98	Buy	+33	New	+$96	﹤0.01%	2065

Other funds holding XBIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Essential Partners's XBIT Position: Q4 2025 in Review

Essential Partners sold out of XBiotech (XBIT) in Q4 2025, closing a stake of 16 shares — an estimated $43 sold.

Essential Partners first reported a position in XBIT in Q2 2025 and held it in 2 quarters. The position peaked at $98 in Q2 2025. 41 funds tracked by Wall St. Rank hold XBIT as of Q4 2025.

Essential Partners reported no remaining XBiotech position as of Q4 2025 after selling out during the quarter.
Essential Partners sold 16 XBiotech shares in Q4 2025, an estimated $43.
Essential Partners first reported a position in XBiotech in Q2 2025 and held it in 2 quarters.
Essential Partners's XBiotech position peaked at $98 in Q2 2025.
41 funds tracked by Wall St. Rank held XBiotech as of Q4 2025.

Based on Essential Partners's 13F filing for Q4 2025, filed 21 May 2026.